Osteoarthritis in dogs: intra-articular platelet-rich plasma vs saline — MAYBE (weak evidence)

In dogs with osteoarthritis (notably elbow/hip), does intra-articular platelet-rich plasma improve objective gait measures vs saline injection?

Shelf #185 · gate-verified and approved by the developer

MAYBE (weak evidence): Intra-articular platelet-rich plasma (PRP) may improve pain, function and gait in dogs with osteoarthritis, but no randomised, blinded, saline-controlled trial in spontaneous canine osteoarthritis was found in the records fetched for this shelf. The saline-controlled evidence is one small client-owned trial in 20 police working dogs with bilateral hip osteoarthritis (Alves 2021), in which PRP gave better results on the majority of pain and function scores than saline over 180 days but whose record states neither randomisation nor blinding and reports no score values, and one experimental study in 12 dogs with surgically induced cruciate/meniscal injury (Cook 2016), in which leukoreduced PRP beat saline on pain (P < .01), lameness, function and range of motion. The named Vilar-programme anchor (Vilar 2018) is an uncontrolled series: force-platform measures improved for 3 months after PRP and waned to nearly initial levels by 6 months. A 2025 critical appraisal of 7 studies concluded the evidence for PRP reducing pain and lameness in canine osteoarthritis is weak. No mortality or survival claim is made, so this pack is not Tier C. Drafted Nov 10, 2026 (VetMed build, topic #185); all figures from abstracts fetched and verified at drafting.

Alves 2021: PRP beat saline on most pain and function scores over 180 days in 20 police dogs with bilateral hip OA — the record reports no score values

Controlled clinical trial with a saline control group (indexed as a veterinary clinical trial; the record states dogs were assigned using statistical software and does not state randomisation or blinding)

Who: Dogs: 20 police working dogs with bilateral hip osteoarthritis (mean age 8.4 ± 2.4 years, mean bodyweight 31.5 ± 5.7 kg; 12 male, 8 female; joints classified moderate in 13 and severe in 7 by the Orthopedic Foundation for Animals grading scheme), assigned to a treatment group (n = 10) receiving two intra-articular administrations of platelet-rich plasma 14 days apart or a control group (n = 10) receiving intra-articular saline at the same moments.

Result: Response was measured with the Canine Brief Pain Inventory, Liverpool Osteoarthritis in Dogs, Canine Orthopedic Index and Hudson Visual Analogue Scale before treatment and at +8, +15, +30, +60, +90, +120, 150 and +180 days. No differences were found between groups at the initial evaluation. The record reports that better results with the majority of scores were observed in the PRP group, in some cases lasting up to the last evaluation moment, that Kaplan-Meier estimators showed PRP produced longer periods with better results in all scores compared with the control group, and that in Cox proportional hazard regression treatment was the covariate influencing all scores (the OFA hip score also influenced two dimensions of the Canine Orthopedic Index). The record's abstract reports no numerical score values for either group, so the size of the benefit cannot be carded.

Watch out: This is the only client-owned, spontaneous-osteoarthritis, saline-controlled PRP trial located at drafting, and it is small (10 dogs per group), its outcomes are owner- and observer-completed pain and function scores, and its record does not state that allocation was randomised or that anyone was blinded — exactly the design features that matter most for subjective scores. The draft anchor for this topic (randomised, blinded PRP trials from the Vilar/Fernández programmes) was not verified: no such saline-controlled blinded trial from those programmes appears in the fetched records (see the Vilar 2018 card).

Alves JC, Santos A, Jorge P. Platelet-rich plasma therapy in dogs with bilateral hip osteoarthritis. BMC Vet Res. 2021;17(1):207. PMID: 34090433. Registry ID: none in the record. MeSH: Animals · Dog Diseases · Dogs · Female · Male · Osteoarthritis, Hip · Platelet-Rich Plasma

Cook 2016 (experimental model): five leukoreduced PRP injections beat saline on pain, lameness, function and range of motion over 6 months

Experimental canine ACL/meniscal-deficiency model with a saline control group (indexed with the MeSH term Random Allocation; the abstract does not state randomisation or blinding in words)

Who: Dogs: 12 dogs in an experimental model — each underwent partial anterior cruciate ligament (ACL) transection and meniscal release in one knee — treated at weeks 1, 2, 3, 6 and 8 after the insult with intra-articular injections (2 ml) of either leukoreduced platelet-rich plasma (autologous conditioned plasma, ACP; n = 6) or saline (n = 6), and assessed over 6 months for comfortable range of motion (CROM), lameness, pain, effusion, kinetics, and radiographic and arthroscopic change.

Result: Saline-treated dogs had significantly more CROM loss (P < .04), significantly more pain (P < .01), significantly more severe lameness (P < .05), significantly lower function (P < .05) and significantly lower %Total Pressure Index in affected hindlimbs (P < .05) compared with ACP-treated dogs. Radiographic osteoarthritis increased significantly (P < .01) over time within each group. At arthroscopy, saline-treated knees showed moderate to severe synovitis, further ACL disruption and medial compartment cartilage loss, while ACP-treated knees showed evidence of ACL repair and less severe synovitis; ACL histopathology was significantly less severe in ACP-treated knees (P < .05), while ACL material properties were closer to normal on ACP but the differences were not statistically significant.

Watch out: This is a surgically induced injury model in 12 research dogs, not spontaneous osteoarthritis in patients: the treatment was aimed in part at ligament and meniscal healing after an acute insult, and the group sizes are 6 dogs. It supports a biological effect of leukoreduced PRP inside a damaged joint; it does not by itself establish benefit for a pet dog with chronic osteoarthritis.

Cook JL, Smith PA, Bozynski CC, Kuroki K, Cook CR, Stoker AM, Pfeiffer FM. Multiple injections of leukoreduced platelet rich plasma reduce pain and functional impairment in a canine model of ACL and meniscal deficiency. J Orthop Res. 2016;34(4):607-15. PMID: 26403590. Registry ID: none in the record. MeSH: Animals · Anterior Cruciate Ligament Injuries · Arthralgia · Arthroscopy · Disease Models, Animal · Dogs · Injections, Intra-Articular · Knee Injuries · Osteoarthritis, Knee · Platelet-Rich Plasma · Random Allocation · Tibial Meniscus Injuries

Vilar 2018 (the named anchor programme): PRP improved force-platform gait measures for 3 months in 12 bulldogs with post-rupture stifle disease — then the effect waned to near baseline by 6 months

Single-arm treated series with objective force-platform measurement and a sound-dog reference group (no saline or placebo arm)

Who: Dogs: 12 lame client-owned English bulldogs with stifle degenerative joint disease secondary to cranial cruciate ligament rupture, treated with 4 intra-articular injections of a platelet-rich plasma derivative at 30-day intervals; 10 untreated, sound English bulldogs were used as a reference group (not as a saline control). Peak vertical force (PVF), vertical impulse (VI), stance time (ST) and angular range of motion (AROM) were measured on a force platform with electrogoniometers.

Result: Mean values of PVF, VI, ST and AROM improved within the first 3 months post-treatment in the treated group, with mean measured changes increasing to a maximum of 4.56% body weight gain (PVF), 1.5% body weight/second (VI), 0.07 seconds (ST) and 6.18 degrees (AROM). The effects declined progressively after the treatment interval, ending at nearly initial levels after 6 months. The authors concluded that dogs treated with intra-articular PRP had improved gait measures over time, with the duration of effect waning by the end of the post-treatment period.

Watch out: There is no injected control group in this study: the comparison is against the dogs' own baselines and against sound dogs, so natural fluctuation after cruciate injury, concurrent care and time cannot be separated from a PRP effect. This card is included because the Vilar programme was named as this topic's anchor — fetched and verified, it is an uncontrolled series, not the randomised, blinded, saline-controlled trial the draft described.

Vilar JM, Manera ME, Santana A, Spinella G, Rodriguez O, Rubio M, Carrillo JM, Sopena J, Batista M. Effect of leukocyte-reduced platelet-rich plasma on osteoarthritis caused by cranial cruciate ligament rupture: A canine gait analysis model. PLoS One. 2018;13(3):e0194752. PMID: 29554150. Registry ID: none in the record. MeSH: Animals · Anterior Cruciate Ligament · Anterior Cruciate Ligament Injuries · Blood Component Transfusion · Dog Diseases · Dogs · Female · Leukocyte Count · Leukocytes · Male · Osteoarthritis · Platelet-Rich Plasma · Rupture

Cai & Zaki 2025: across 7 studies, the evidence that PRP reduces pain and lameness in canine OA is weak — large randomised, blinded controlled trials are still required

Critical appraisal / review of the intra-articular PRP vs placebo literature in dogs with osteoarthritis (the record's own study type)

Who: Dogs: a critical appraisal of the current literature on intra-articular platelet-rich plasma compared with placebo for the clinical outcomes of lameness and pain in dogs with osteoarthritis, covering 7 studies.

Result: The appraisal concludes that findings from the 7 studies indicate the current evidence supporting the effectiveness of PRP in reducing pain and lameness is weak, and that further research in the form of large, randomised, blinded controlled clinical trials is required to assess the efficacy of PRP. The record gives no pooled effect size.

Watch out: A review card cannot add primary evidence; it is carded because it is the fetched record that independently grades this exact question, and its verdict matches what the primary records above show. Clinicians should not read the positive direction of the small studies as a measured, blinded treatment effect.

Cai XL, Zaki S. The effect of intra-articular platelet-rich plasma injection on pain and lameness in dogs with osteoarthritis. Aust Vet J. 2025;103(10):663-671. PMID: 40692209. Registry ID: none in the record. MeSH: Animals · Dogs · Platelet-Rich Plasma · Lameness, Animal · Osteoarthritis · Dog Diseases · Injections, Intra-Articular · Pain · Pain Management

Synthesis: direction positive, design weak — no blinded saline-controlled trial in spontaneous canine OA exists in the fetched records

Synthesis

Who: Synthesis of the cards above: Alves 2021 (saline-controlled clinical trial, 20 police dogs with bilateral hip osteoarthritis), Cook 2016 (saline-controlled experimental ACL/meniscal model, 12 dogs), Vilar 2018 (single-arm force-platform series, 12 bulldogs) and Cai & Zaki 2025 (critical appraisal of 7 studies).

Result: Every fetched comparison points the same way — PRP-treated joints did better than saline-treated joints in one small client-owned hip trial and in one small experimental injury model, and objectively measured gait improved for about 3 months in an uncontrolled series before waning to near baseline by 6 months. But the claim-carrying designs are missing: no randomised, blinded, saline-controlled trial in dogs with spontaneous osteoarthritis was located, the one clinical saline-controlled trial does not state randomisation or blinding and reports no score values in its record, and the independent 2025 appraisal of 7 studies grades the evidence as weak. MAYBE (weak evidence) is the honest stamp.

Watch out: PRP preparations differ between studies (including leukocyte-reduced products), joints and diseases differ (hip osteoarthritis, post-rupture stifle disease, an induced injury model), and none of the fetched records reports a mortality, survival or lifespan outcome — this pack makes no such claim and is not a Tier C pack.

Synthesis of Alves JC et al. PMID: 34090433; Cook JL et al. PMID: 26403590; Vilar JM et al. PMID: 29554150; Cai XL & Zaki S. PMID: 40692209. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.